Frank Holz
About Frank Holz:
Expertise: Not specified
Tools: Not specified
Their tagsRelated items
Advanced Trial Projects list for this Person with search and filtering
The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study period of 12 months in 30 patients.
Public web page: https://clinicaltrials.gov/study/NCT01914159
Start date: 1st Feb 2013
End date: 31st Mar 2016
